Gopala K Rangan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3423554/publications.pdf

Version: 2024-02-01

66 papers	1,173 citations	516561 16 h-index	414303 32 g-index
66 all docs	66 docs citations	66 times ranked	1606 citing authors

#	Article	IF	Citations
1	Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 2020, 382, 2504-2513.	13.9	281
2	Temporal Relationship between Renal Cyst Development, Hypertension and Cardiac Hypertrophy in a New Rat Model of Autosomal Recessive Polycystic Kidney Disease. Kidney and Blood Pressure Research, 2007, 30, 129-144.	0.9	77
3	NF-kappaB signalling in chronic kidney disease. Frontiers in Bioscience - Landmark, 2009, Volume, 3496.	3.0	71
4	Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology, 2013, 18, 317-330.	0.7	65
5	Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open, 2018, 8, e018794.	0.8	60
6	Sirolimus-Associated Proteinuria and Renal Dysfunction. Drug Safety, 2006, 29, 1153-1161.	1.4	45
7	Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2007, 22, 2175-2182.	0.4	38
8	Dietary Quercetin Augments Activator Protein-1 and Does Not Reduce Nuclear Factor-Î ºB in the Renal Cortex of Rats with Established Chronic Glomerular Disease. Nephron, 2002, 90, 313-319.	0.9	29
9	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	2.1	23
10	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	2.1	21
11	Standardised Outcomes in Nephrologyâ€”Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	0.7	20
12	Identifying patientâ€important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	0.7	20
13	Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. European Journal of Human Genetics, 2021, 29, 760-770.	1.4	20
14	Autosomal Dominant Polycystic Kidney Disease: A Path Forward. Seminars in Nephrology, 2015, 35, 524-537.	0.6	18
15	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management. Seminars in Nephrology, 2015, 35, 572-581.e17.	0.6	17
16	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Intracranial Aneurysms. Seminars in Nephrology, 2015, 35, 612-617.e20.	0.6	17
17	Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease. , 2022, 1, .		17
18	Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease. PLoS ONE, 2019, 14, e0209186.	1.1	16

#	Article	IF	Citations
19	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	2.1	16
20	Constitutive renal Rel/nuclear factor-Î¹B expression in Lewis polycystic kidney disease rats. World Journal of Nephrology, 2016, 5, 339.	0.8	16
21	Therapeutic role of sirolimus in non-transplant kidney disease. , 2009, 123, 187-206.		15
22	Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963â€“2014). Population Health Metrics, 2017, 15, 7.	1.3	15
23	Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease. PLoS ONE, 2016, 11, e0164193.	1.1	15
24	Chronic effects of dietary vitamin D deficiency without increased calcium supplementation on the progression of experimental polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2013, 305, F574-F582.	1.3	14
25	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. Seminars in Nephrology, 2015, 35, 618-622.e5.	0.6	14
26	Patient needs and priorities for patient navigator programmes in chronic kidney disease: a workshop report. BMJ Open, 2020, 10, e040617.	0.8	14
27	Clinical characteristics and outcomes of hyponatraemia associated with oral water intake in adults: a systematic review. BMJ Open, 2021, 11, e046539.	0.8	13
28	Adenine Phosphoribosyltransferase Deficiency: A Potentially Reversible Cause of CKD. Kidney International Reports, 2019, 4, 1161-1170.	0.4	12
29	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease. Seminars in Nephrology, 2015, 35, 603-606.e3.	0.6	11
30	A systematic review to determine the most effective interventions to increase water intake. Nephrology, 2016, 21, 860-869.	0.7	11
31	Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis. Experimental Biology and Medicine, 2018, 243, 428-436.	1.1	11
32	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. Seminars in Nephrology, 2015, 35, 545-549.e2.	0.6	10
33	Up-Regulation of DNA Damage Response Signaling in Autosomal Dominant Polycystic Kidney Disease. American Journal of Pathology, 2021, 191, 902-920.	1.9	10
34	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. Seminars in Nephrology, 2015, 35, 582-589.e17.	0.6	9
35	The role of DNA damage as a therapeutic target in autosomal dominant polycystic kidney disease. Expert Reviews in Molecular Medicine, 2019, 21, e6.	1.6	9
36	A protocol for the identification and validation of novel genetic causes of kidney disease. BMC Nephrology, 2015, 16, 152.	0.8	8

#	Article	IF	Citations
37	Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor-Î¹B activity in autosomal dominant polycystic kidney disease cells. BMC Nephrology, 2015, 16, 212.	0.8	8
38	Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease. Cells, 2021, 10, 532.	1.8	8
39	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Screening for Polycystic Kidney Disease. Seminars in Nephrology, 2015, 35, 557-564.e6.	0.6	7
40	KHA-CARI Autosomal Dominant Kidney Disease Guideline: Management of Chronic Pain. Seminars in Nephrology, 2015, 35, 607-611.e3.	0.6	6
41	Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease. Laboratory Investigation, 2020, 100, 696-711.	1.7	6
42	Mild gentamicin nephrotoxicity reduces the progression of chronic adriamycin nephrosis. Nephrology, 1998, 4, 57-64.	0.7	5
43	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling. Seminars in Nephrology, 2015, 35, 550-556.e1.	0.6	5
44	â€˜A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	0.8	5
45	RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease) Tj ETQq1 1 0.784314 rgBT /Overlock 1 0 retrospective cohort study. BMJ Open, 2020, 10, e034103.	0.8	5
46	Regression of Peritubular Capillaries Coincides with Angiogenesis and Renal Cyst Growth in Experimental Polycystic Kidney Disease . International Journal of Nephrology and Renovascular Disease, 2020, Volume 13, 53-64.	0.8	5
47	Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?. World Journal of Nephrology, 2018, 7, 51-57.	0.8	5
48	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Monitoring Disease Progression. Seminars in Nephrology, 2015, 35, 565-571.e18.	0.6	4
49	Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS ONE, 2021, 16, e0252479.	1.1	4
50	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of End-Stage Kidney Disease. Seminars in Nephrology, 2015, 35, 595-602.e12.	0.6	3
51	Current and emerging treatment options to prevent renal failure due to autosomal dominant polycystic kidney disease. Expert Opinion on Orphan Drugs, 2020, 8, 285-302.	0.5	3
52	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. CKJ: Clinical Kidney Journal, 2022, 15, 407-416.	1.4	3
53	Role of DNA-Dependent Protein Kinase in Mediating Cyst Growth in Autosomal Dominant Polycystic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 10512.	1.8	3
54	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care. Seminars in Nephrology, 2015, 35, 590-594.e5.	0.6	2

#	Article	IF	Citations
55	Long-term dietary nitrate supplementation does not reduce renal cyst growth in experimental autosomal dominant polycystic kidney disease. PLoS ONE, 2021, 16, e0248400.	1.1	2
56	Autosomal dominant polycystic kidney disease (ADPKD) is associated with coronary arterial dilatation in end-stage renal failure patients. CKJ: Clinical Kidney Journal, 2012, 5, 41-43.	1.4	1
57	Levels of haloacetic acids in tap water in an urban Australian city and its relevance to autosomal dominant polycystic kidney disease. Kidney International, 2014, 85, 1471.	2.6	1
58	Progression of polycystic kidney diseaseâ€"a lack of progress?. Nature Reviews Nephrology, 2014, 10, 489-491.	4.1	1
59	Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population. Nutrients, 2018, 10, 1051.	1.7	1
60	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. Nutrients, 2020, 12, 3376.	1.7	1
61	Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease. Nephrology, 2021, 26, 920-930.	0.7	1
62	Effect of Nephrotoxins on Tubulointerstitial Injury and NF-ÎºB Activation in Adriamycin Nephropathy. Renal Failure, 2005, 27, 609-614.	0.8	0
63	Mild gentamicin nephrotoxicity reduces the progression of chronic adriamycin nephrosis. Nephrology, 1998, 4, 57-64.	0.7	0
64	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. Kidney International Reports, 2021, 6, 1032-1040.	0.4	0
65	Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease. Journal of Cardiovascular Development and Disease, 2021, 8, 144.	0.8	0
66	Recurrent hyperparathyroidism presenting as spinal cord compression. Kidney International, 2022, 101, 834.	2.6	0